Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 14
Commentary
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 3,261 | Dovepress* | 3,141+ | 62 | 3,203 | |
| PubMed Central* | 120 | 52 | 172 | ||
| Totals | 3,261 | 114 | 3,375 | ||
| *Since 23 June 2023 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 19 | 0 | 0 | 1 | 8 | 10 |
View citations on PubMed Central and Google Scholar